Switch to:
Also traded in: Germany, Mexico

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
Cash-to-Debt 0.05
ACT's Cash-to-Debt is ranked lower than
94% of the 859 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.03 vs. ACT: 0.05 )
Ranked among companies with meaningful Cash-to-Debt only.
ACT' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.01  Med: 0.54 Max: 43.62
Current: 0.05
0.01
43.62
Equity-to-Asset 0.66
ACT's Equity-to-Asset is ranked higher than
53% of the 788 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.64 vs. ACT: 0.66 )
Ranked among companies with meaningful Equity-to-Asset only.
ACT' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.25  Med: 0.64 Max: 0.93
Current: 0.66
0.25
0.93
Debt-to-Equity 0.33
ACT's Debt-to-Equity is ranked lower than
53% of the 596 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.32 vs. ACT: 0.33 )
Ranked among companies with meaningful Debt-to-Equity only.
ACT' s Debt-to-Equity Range Over the Past 10 Years
Min: 0.01  Med: 0.31 Max: 1.8
Current: 0.33
0.01
1.8
Debt-to-EBITDA 3.69
ACT's Debt-to-EBITDA is ranked lower than
99% of the 495 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.92 vs. ACT: 3.69 )
Ranked among companies with meaningful Debt-to-EBITDA only.
ACT' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -15.65  Med: 4.46 Max: 64.18
Current: 3.69
-15.65
64.18
Interest Coverage 0.37
ACT's Interest Coverage is ranked lower than
99% of the 648 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 86.08 vs. ACT: 0.37 )
Ranked among companies with meaningful Interest Coverage only.
ACT' s Interest Coverage Range Over the Past 10 Years
Min: 0.37  Med: 8.73 Max: 12.7
Current: 0.37
0.37
12.7
Piotroski F-Score: 6
Altman Z-Score: 1.13
Beneish M-Score: -2.52
WACC vs ROIC
6.03%
-0.60%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 7/10

vs
industry
vs
history
Operating Margin % 2.21
ACT's Operating Margin % is ranked lower than
68% of the 801 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.97 vs. ACT: 2.21 )
Ranked among companies with meaningful Operating Margin % only.
ACT' s Operating Margin % Range Over the Past 10 Years
Min: -39.29  Med: 2.23 Max: 14.13
Current: 2.21
-39.29
14.13
Net Margin % 14.50
ACT's Net Margin % is ranked lower than
73% of the 802 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.32 vs. ACT: 14.50 )
Ranked among companies with meaningful Net Margin % only.
ACT' s Net Margin % Range Over the Past 10 Years
Min: -34.87  Med: 5.43 Max: 102.76
Current: 14.5
-34.87
102.76
ROE % 3.08
ACT's ROE % is ranked lower than
67% of the 832 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.94 vs. ACT: 3.08 )
Ranked among companies with meaningful ROE % only.
ACT' s ROE % Range Over the Past 10 Years
Min: -11.23  Med: 6.44 Max: 19.24
Current: 3.08
-11.23
19.24
ROA % 2.06
ACT's ROA % is ranked lower than
65% of the 871 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.88 vs. ACT: 2.06 )
Ranked among companies with meaningful ROA % only.
ACT' s ROA % Range Over the Past 10 Years
Min: -4.32  Med: 3.67 Max: 11.32
Current: 2.06
-4.32
11.32
ROC (Joel Greenblatt) % -39.99
ACT's ROC (Joel Greenblatt) % is ranked lower than
86% of the 855 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 11.23 vs. ACT: -39.99 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
ACT' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -547.05  Med: 2.21 Max: 38.44
Current: -39.99
-547.05
38.44
3-Year Revenue Growth Rate 30.90
ACT's 3-Year Revenue Growth Rate is ranked higher than
91% of the 689 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.80 vs. ACT: 30.90 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
ACT' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -16.3  Med: 17.55 Max: 40.4
Current: 30.9
-16.3
40.4
3-Year EPS without NRI Growth Rate -2.00
ACT's 3-Year EPS without NRI Growth Rate is ranked lower than
65% of the 663 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 8.90 vs. ACT: -2.00 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
ACT' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: 0  Med: 0.75 Max: 94.3
Current: -2
0
94.3
» ACT's 30-Y Financials

Financials (Next Earnings Date: 2019-02-22 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Insider Trades

Latest Guru Trades with ACT

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

Guru Date Action
Impact Price Range
(Average)*
Change from Average Comment Current Shares
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Allergan PLC does not have enough historical financial data to display Peter Lynch Chart.

Preferred stocks of Allergan PLC

SymbolPriceYieldDescription
AGNpA.PFD543.502.535 1/2 % Cum.Conv.Pref.Shs 2015-1.3.18 Series -A-

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic    NAICS: 325412    SIC: 2834
Compare:XTER:MRK, NYSE:ZTS, SHSE:600276, TSE:4502, NAS:MYL, TSE:4523, NSE:SUNPHARMA, SHSE:600518, NYSE:TEVA, TSE:4507, SZSE:000538, SHSE:600196, XPAR:IPN, OCSE:LUN, NYSE:PRGO, TSE:4508, SZSE:000963, XSWX:VIFN, SZSE:300122, JSE:APN » details
Traded in other countries:A60.Germany, AGN N.Mexico,
Headquarter Location:Ireland
Allergan PLC is a specialty pharmaceutical company engaged in the development, manufacturing, marketing, and distribution of brand name pharmaceutical products, medical aesthetics, biosimilar and OTC pharmaceutical products.

Allergan is one of the largest specialty pharmaceutical manufacturers. It specializes in aesthetics, ophthalmology, women's health, gastrointestinal, and central nervous system products. In 2016, Allergan sold its generics and distribution segments to Teva.

Top Ranked Articles about Allergan PLC

Stocks That Fell to 3-Year Lows in the Week of Nov. 30 Allergan PLC (ACT), Schlumberger Ltd. (SLB), General Mills Inc. (GIS) and Noble Energy Inc. (NBL) have declined to their 3-year lows
Allergan PLC (NYSE:ACT), Schlumberger Ltd. (NYSE:SLB), General Mills Inc. (NYSE:GIS), and Noble Energy Inc. (NYSE:NBL) have declined to their three-year lows. Read more...
Allergan Makes New Appointments to Finance Leadership Team
Allergan to Present at the 2018 Citi Global Healthcare Conference
Allergan Announces FDA Acceptance of Supplemental New Drug Application for AVYCAZ® (ceftazidime and avibactam)
Stocks That Fell to 3-Year Lows in the Week of Nov. 16 Allergan PLC, Celgene Corp., WPP PLC and Invesco Ltd. (IVZ) have declined to their respective 3-year lows
Allergan PLC (NYSE:ACT), Celgene Corp. (NASDAQ:CELG), WPP PLC (NYSE:WPP) and Invesco Ltd. (NYSE:IVZ) have declined to their three-year lows. Read more...
Allergan to Present at Credit Suisse 27th Annual Healthcare Conference
Jerome Dodson Comments on Allergan Guru stock highlight
Pharmaceutical company Allergan (NYSE:AGN) added 72 bps to the Fund’s return, as the stock went from $166.72 to $190.48 with a total return of 14.7%. The shares rallied after the company reported better-than-expected earnings and raised guidance for the remainder of the year. The aesthetics franchise continues to show robust growth, and management is bullish on the long-term outlook for this business, expecting that it will double over the next five to seven years. As the shares appreciated, we trimmed our position to take some profits. Read more...
Allergan Declares Fourth Quarter 2018 Cash Dividend of $0.72 Per Ordinary Share
CoolSculpting® And Kristin Davis Partner To Overcome Denim Denial Blues
Allergan and The Allergan Foundation Support U.S. Veterans With "Heroes MAKE America" Sponsorship

Ratios

vs
industry
vs
history
PE Ratio 22.86
ACT's PE Ratio is ranked lower than
99.99% of the 557 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 23.77 vs. ACT: 22.86 )
Ranked among companies with meaningful PE Ratio only.
ACT' s PE Ratio Range Over the Past 10 Years
Min: 4.95  Med: 22.3 Max: 366.63
Current: 22.86
4.95
366.63
Forward PE Ratio 9.40
ACT's Forward PE Ratio is ranked higher than
88% of the 111 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 21.60 vs. ACT: 9.40 )
Ranked among companies with meaningful Forward PE Ratio only.
N/A
PE Ratio without NRI 19.47
ACT's PE Ratio without NRI is ranked lower than
99.99% of the 556 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 24.20 vs. ACT: 19.47 )
Ranked among companies with meaningful PE Ratio without NRI only.
ACT' s PE Ratio without NRI Range Over the Past 10 Years
Min: 10.94  Med: 23.16 Max: 119.54
Current: 19.47
10.94
119.54
Price-to-Owner-Earnings 12.67
ACT's Price-to-Owner-Earnings is ranked lower than
99.99% of the 324 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 31.95 vs. ACT: 12.67 )
Ranked among companies with meaningful Price-to-Owner-Earnings only.
ACT' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 2.77  Med: 18.17 Max: 1421.16
Current: 12.67
2.77
1421.16
PB Ratio 0.72
ACT's PB Ratio is ranked higher than
92% of the 819 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.64 vs. ACT: 0.72 )
Ranked among companies with meaningful PB Ratio only.
ACT' s PB Ratio Range Over the Past 10 Years
Min: 0.68  Med: 1.68 Max: 5.9
Current: 0.72
0.68
5.9
PS Ratio 3.16
ACT's PS Ratio is ranked lower than
57% of the 775 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.10 vs. ACT: 3.16 )
Ranked among companies with meaningful PS Ratio only.
ACT' s PS Ratio Range Over the Past 10 Years
Min: 0.99  Med: 2.38 Max: 13.79
Current: 3.16
0.99
13.79
Price-to-Free-Cash-Flow 8.84
ACT's Price-to-Free-Cash-Flow is ranked higher than
89% of the 298 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 30.84 vs. ACT: 8.84 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
ACT' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 7.27  Med: 18.76 Max: 301.76
Current: 8.84
7.27
301.76
Price-to-Operating-Cash-Flow 8.41
ACT's Price-to-Operating-Cash-Flow is ranked higher than
85% of the 392 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 22.00 vs. ACT: 8.41 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
ACT' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 6.06  Med: 14.94 Max: 94.47
Current: 8.41
6.06
94.47
EV-to-EBIT -103.23
ACT's EV-to-EBIT is ranked lower than
99.99% of the 572 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 17.85 vs. ACT: -103.23 )
Ranked among companies with meaningful EV-to-EBIT only.
ACT' s EV-to-EBIT Range Over the Past 10 Years
Min: -310.4  Med: 8.95 Max: 104.6
Current: -103.23
-310.4
104.6
EV-to-EBITDA 11.46
ACT's EV-to-EBITDA is ranked lower than
96% of the 597 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 15.24 vs. ACT: 11.46 )
Ranked among companies with meaningful EV-to-EBITDA only.
ACT' s EV-to-EBITDA Range Over the Past 10 Years
Min: -47.1  Med: 13.8 Max: 589.4
Current: 11.46
-47.1
589.4
EV-to-Revenue 4.57
ACT's EV-to-Revenue is ranked lower than
66% of the 795 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.24 vs. ACT: 4.57 )
Ranked among companies with meaningful EV-to-Revenue only.
ACT' s EV-to-Revenue Range Over the Past 10 Years
Min: 1.2  Med: 3.3 Max: 20.8
Current: 4.57
1.2
20.8
Shiller PE Ratio 52.99
ACT's Shiller PE Ratio is ranked lower than
79% of the 252 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 32.75 vs. ACT: 52.99 )
Ranked among companies with meaningful Shiller PE Ratio only.
ACT' s Shiller PE Ratio Range Over the Past 10 Years
Min: 18.96  Med: 59.04 Max: 2307.73
Current: 52.99
18.96
2307.73
Current Ratio 0.92
ACT's Current Ratio is ranked lower than
87% of the 855 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.39 vs. ACT: 0.92 )
Ranked among companies with meaningful Current Ratio only.
ACT' s Current Ratio Range Over the Past 10 Years
Min: 0.92  Med: 2.93 Max: 9.8
Current: 0.92
0.92
9.8
Quick Ratio 0.78
ACT's Quick Ratio is ranked lower than
80% of the 855 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.87 vs. ACT: 0.78 )
Ranked among companies with meaningful Quick Ratio only.
ACT' s Quick Ratio Range Over the Past 10 Years
Min: 0.78  Med: 2.02 Max: 8.82
Current: 0.78
0.78
8.82
Days Inventory 152.86
ACT's Days Inventory is ranked lower than
67% of the 755 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 119.80 vs. ACT: 152.86 )
Ranked among companies with meaningful Days Inventory only.
ACT' s Days Inventory Range Over the Past 10 Years
Min: 108.11  Med: 132.08 Max: 369.82
Current: 152.86
108.11
369.82
Days Sales Outstanding 64.35
ACT's Days Sales Outstanding is ranked higher than
68% of the 770 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 81.76 vs. ACT: 64.35 )
Ranked among companies with meaningful Days Sales Outstanding only.
ACT' s Days Sales Outstanding Range Over the Past 10 Years
Min: 43.91  Med: 67 Max: 197.04
Current: 64.35
43.91
197.04
Days Payable 47.80
ACT's Days Payable is ranked lower than
72% of the 758 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 76.32 vs. ACT: 47.80 )
Ranked among companies with meaningful Days Payable only.
ACT' s Days Payable Range Over the Past 10 Years
Min: 28.64  Med: 62.26 Max: 109.48
Current: 47.8
28.64
109.48

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -7.50
ACT's 3-Year Average Share Buyback Ratio is ranked lower than
56% of the 571 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: -5.30 vs. ACT: -7.50 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
ACT' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -45.6  Med: -6.7 Max: 2
Current: -7.5
-45.6
2

Valuation & Return

vs
industry
vs
history
Price-to-Intrinsic-Value-Projected-FCF 0.61
ACT's Price-to-Intrinsic-Value-Projected-FCF is ranked higher than
90% of the 374 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.11 vs. ACT: 0.61 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
ACT' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 0.56  Med: 1.14 Max: 4.58
Current: 0.61
0.56
4.58
Price-to-Median-PS-Value 1.33
ACT's Price-to-Median-PS-Value is ranked lower than
84% of the 743 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.94 vs. ACT: 1.33 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
ACT' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.52  Med: 1.58 Max: 5.18
Current: 1.33
0.52
5.18
Earnings Yield (Greenblatt) % -0.97
ACT's Earnings Yield (Greenblatt) % is ranked lower than
80% of the 867 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.31 vs. ACT: -0.97 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
ACT' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -11.4  Med: 1 Max: 12.1
Current: -0.97
-11.4
12.1
Forward Rate of Return (Yacktman) % 9.80
ACT's Forward Rate of Return (Yacktman) % is ranked higher than
50% of the 421 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 8.96 vs. ACT: 9.80 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) % only.
ACT' s Forward Rate of Return (Yacktman) % Range Over the Past 10 Years
Min: -8  Med: 11.1 Max: 21.2
Current: 9.8
-8
21.2

More Statistics

Revenue (TTM) (Mil) $16,033.80
52-Week Range $23.05 - 317.72
Shares Outstanding (Mil)392.44

Piotroski F-Score Details

Piotroski F-Score: 66
Positive ROAY
Positive CFROAY
Higher ROA yoyY
CFROA > ROAY
Lower Leverage yoyY
Higher Current Ratio yoyN
Less Shares Outstanding yoyN
Higher Gross Margin yoyN
Higher Asset Turnover yoyY

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}